February 16, 2005Open Access
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Structured PICO
Does celecoxib increase the risk of cardiovascular events in patients undergoing colorectal adenoma prevention?
P
Population
Patients in a clinical trial for colorectal adenoma prevention
I
Intervention
Celecoxib
O
Outcome
Composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failurecomposite
Celecoxib use is associated with a dose-related increase in serious cardiovascular events, adding to the evidence of cardiovascular harm from COX-2 inhibitors.
Abstract
Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure. In light of recent reports of cardiovascular harm associated with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Scott D. Solomon
Brigham and Women's Hospital
John J.V. McMurray
British Heart Foundation
Marc A. Pfeffer
Heart Failure & Transplant
Journals
New England Journal of Medicine
Actions
Institutions
Harvard University
Brigham and Women's Hospital
Memorial Sloan Kettering Cancer Center
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...